You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

man on ladder

SHINGRIX herpes zoster vaccine [recombinant, adjuvanted]

If you can prevent shingles suffering, why wouldn't you?

Date of preparation: September 2023 PM-IE-SGX-WCNT-230004

Prescribing information link

Quick links

More Information

Get more from GSKpro

Get access to exclusive events on the topics that matter to you, free patient resources including patient support materials, demo devices and updates on the latest in HIV/AIDS, respiratory, oncology and Vaccines

Register in 2 Minutes

References

  1. Cahn P, Sierra Madero J, Arribas JR, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infection—3-year results from the GEMINI studies. Presented at: HIV Glasgow 2020; October 5-8, 2020; Virtual. Poster P018.
  2. Arexvy, Summary of Product Characteristics (SPC), available at: https://www.medicines.ie/medicines/arexvy-powder-and-suspension-for-suspension-for-injection-35441/spc. Last Accessed: September 2024
  3. Zejula, Summary of Product Characteristics (SPC), available at: https://www.medicines.ie/medicines/zejula-100-mg-hard-capsules-35060/spc Last Accessed: September 2024
  4. Shingrix, Summary of Product Characteristics (SPC), available at: https://www.medicines.ie/medicines/shingrix-powder-and-suspension-for-suspension-for-injection-herpes-zoster-vaccine-recombinant-adjuvanted--35192/spc Last Accessed: September 2024

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the GSK group of companies.

PM-IE-NA-WCNT-220010 Date of Preparation: September 2024